company background image
OCPH

October PharmaECASE:OCPH Stock Report

Market Cap

ج.م660.0m

7D

0%

1Y

10.0%

Updated

17 Oct, 2021

Data

Company Financials
OCPH fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance6/6
Financial Health4/6
Dividends2/6

OCPH Overview

October Pharma S.A.E manufactures and sells pharmaceutical products.

Price History & Performance

Summary of all time highs, changes and price drops for October PharmaE
Historical stock prices
Current Share Priceج.م110.00
52 Week Highج.م90.00
52 Week Lowج.م132.00
Beta1.45
1 Month Change0%
3 Month Change15.74%
1 Year Change10.00%
3 Year Change83.36%
5 Year Changen/a
Change since IPO1,057.89%

Recent News & Updates

Shareholder Returns

OCPHEG PharmaceuticalsEG Market
7D0%-2.1%1.3%
1Y10.0%1.9%10.0%

Return vs Industry: OCPH exceeded the EG Pharmaceuticals industry which returned 1.8% over the past year.

Return vs Market: OCPH exceeded the EG Market which returned 8.2% over the past year.

Price Volatility

Is OCPH's price volatile compared to industry and market?
OCPH volatility
OCPH Beta1.45
Industry Beta0.86
Market Beta1

Stable Share Price: OCPH is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: OCPH's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/an/ahttps://www.octoberpharma.com

October Pharma S.A.E manufactures and sells pharmaceutical products. The company offers cardiovascular, CNS, cold and chest, dermatology, diabetology, gastroenterology, hepatology, NSAID’s, and urology medicines, as well as antibiotics and multivitamins. It provides its products in solid forms, such as tablets, capsules, and powders; liquid forms comprising syrups, drops, solutions, and sprays; creams and suppositories; soft gelatin capsules; and ampoules and vials.

October PharmaE Fundamentals Summary

How do October PharmaE's earnings and revenue compare to its market cap?
OCPH fundamental statistics
Market Capج.م660.00m
Earnings (TTM)ج.م130.84m
Revenue (TTM)ج.م619.23m

5.0x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OCPH income statement (TTM)
Revenueج.م619.23m
Cost of Revenueج.م318.96m
Gross Profitج.م300.26m
Expensesج.م169.42m
Earningsج.م130.84m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)21.81
Gross Margin48.49%
Net Profit Margin21.13%
Debt/Equity Ratio75.4%

How did OCPH perform over the long term?

See historical performance and comparison

Dividends

2.7%

Current Dividend Yield

14%

Payout Ratio

Valuation

Is October PharmaE undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OCPH (EGP110) is trading below our estimate of fair value (EGP566.01)

Significantly Below Fair Value: OCPH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OCPH is good value based on its PE Ratio (5x) compared to the EG Pharmaceuticals industry average (5.5x).

PE vs Market: OCPH is good value based on its PE Ratio (5x) compared to the EG market (12.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OCPH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OCPH is overvalued based on its PB Ratio (2.3x) compared to the EG Pharmaceuticals industry average (1.3x).


Future Growth

How is October PharmaE forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as October PharmaE has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has October PharmaE performed over the past 5 years?

29.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OCPH has high quality earnings.

Growing Profit Margin: OCPH's current net profit margins (21.1%) are higher than last year (11.7%).


Past Earnings Growth Analysis

Earnings Trend: OCPH's earnings have grown significantly by 29% per year over the past 5 years.

Accelerating Growth: OCPH's earnings growth over the past year (112.2%) exceeds its 5-year average (29% per year).

Earnings vs Industry: OCPH earnings growth over the past year (112.2%) exceeded the Pharmaceuticals industry 10%.


Return on Equity

High ROE: OCPH's Return on Equity (45.2%) is considered outstanding.


Financial Health

How is October PharmaE's financial position?


Financial Position Analysis

Short Term Liabilities: OCPH's short term assets (EGP400.6M) exceed its short term liabilities (EGP279.1M).

Long Term Liabilities: OCPH's short term assets (EGP400.6M) exceed its long term liabilities (EGP43.7M).


Debt to Equity History and Analysis

Debt Level: OCPH's debt to equity ratio (75.4%) is considered high.

Reducing Debt: OCPH's debt to equity ratio has increased from 18.2% to 75.4% over the past 5 years.

Debt Coverage: OCPH's debt is well covered by operating cash flow (44.2%).

Interest Coverage: OCPH's interest payments on its debt are well covered by EBIT (7.2x coverage).


Balance Sheet


Dividend

What is October PharmaE current dividend yield, its reliability and sustainability?

2.73%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: OCPH's dividend (2.73%) is higher than the bottom 25% of dividend payers in the EG market (2.69%).

High Dividend: OCPH's dividend (2.73%) is low compared to the top 25% of dividend payers in the EG market (7.43%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, OCPH has been paying a dividend for less than 10 years.

Growing Dividend: OCPH has only been paying a dividend for 4 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (13.8%), OCPH's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average board tenure


CEO

October PharmaE has no CEO, or we have no data on them.


Board Members

Experienced Board: OCPH's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

October Pharma S.A.E's employee growth, exchange listings and data sources


Key Information

  • Name: October Pharma S.A.E
  • Ticker: OCPH
  • Exchange: CASE
  • Founded: 1987
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ج.م660.000m
  • Shares outstanding: 6.00m
  • Website: https://www.octoberpharma.com

Location

  • October Pharma S.A.E
  • Piece #190
  • Street #25
  • Cairo
  • Egypt

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/17 14:31
End of Day Share Price2021/10/14 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.